Table 2

Comparison of reduced nine-paired joint set with existing six-paired and seven-paired joint sets: change in GLOESS and components

Joint countnMean change baseline to week 24 (95% CI)SRM
Nine-paired* joint set84GLOESS–6.4 (–7.9 to –4.9)–0.95
 SH–6.1 (–7.5 to –4.7)–0.95
 PD–5.2 (–6.5 to –3.9)–0.86
 JE–3.4 (–4.6 to –2.1)–0.59
Six-paired† joint set2485GLOESS–5.3 (–6.5 to –4.2)–0.99
 SH–5.1 (–6.2 to –4.0)–0.99
 PD–4.8 (–5.8 to –3.8)–1.02
 JE–2.9 (–3.8 to –1.9)–0.65
Seven-paired‡ joint set2585GLOESS–6.6 (–8.0 to –5.3)–1.05
 SH–6.3 (–7.6 to –5.0)–1.07
 PD–6.2 (–7.5 to –4.9)–1.04
 JE–3.2 (–4.3 to –2.1)–0.63
  • n=number of patients with both baseline and postbaseline measurements.

  • *MCP1, MCP4, PIP2, wrist, shoulder, elbow, knee, MTP3, MTP5 bilaterally.

  • †MCP2, MCP3, wrist, elbow, knee, ankle bilaterally.

  • ‡MCP2, MCP3, PIP2, PIP3, wrist, MTP2, MTP5 bilaterally. Excludes PDUS score from sites that experienced technical and quality issues with PDUS scoring and compliance issues.

  • GLOESS, Global OMERACT–EULAR (Outcome Measures in Rheumatology–European League Against Rheumatism) Synovitis Score; JE, joint effusion; MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; PD, power Doppler; PDUS, PD and greyscale ultrasound; PIP, proximal interphalangeal joint; SH, synovial hyperplasia; SRM, standardised response mean.